David A. Siegel Savara Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Savara Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 289,915 shares of SVRA stock, worth $858,148. This represents 0.0% of its overall portfolio holdings.

Number of Shares

289,915

Previous 404,215 28.28%

Holding current value

$858,148

Previous $1.63 Million 24.51%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.96 - $5.07 $452,628 - $579,501	-114,300 Reduced 28.28%	289,915 $1.23 Million
Q2 2024 Aug 14, 2024	SELL	$3.66 - $5.34 $347,334 - $506,766	-94,900 Reduced 19.01%	404,215 $1.63 Million
Q1 2024 May 15, 2024	BUY	$4.19 - $5.59 $1.94 Million - $2.59 Million	462,900 Added 1278.2%	499,115 $2.49 Million
Q4 2023 Feb 14, 2024	BUY	$3.18 - $4.9 $45,706 - $70,427	14,373 Added 65.8%	36,215 $170,000
Q3 2023 Nov 14, 2023	SELL	$2.97 - $3.88 $58,725 - $76,719	-19,773 Reduced 47.51%	21,842 $82,000
Q2 2023 Aug 14, 2023	SELL	$1.69 - $3.24 $162,747 - $312,012	-96,300 Reduced 69.83%	41,615 $132,000
Q1 2023 May 15, 2023	SELL	$1.6 - $2.82 $17,600 - $31,020	-11,000 Reduced 7.39%	137,915 $268,000
Q4 2022 Feb 14, 2023	SELL	$1.11 - $1.64 $12,765 - $18,860	-11,500 Reduced 7.17%	148,915 $230,000
Q3 2022 Nov 14, 2022	SELL	$1.36 - $1.88 $3,672 - $5,076	-2,700 Reduced 1.66%	160,415 $249,000
Q2 2022 Aug 15, 2022	SELL	$1.1 - $1.58 $146,960 - $211,088	-133,600 Reduced 45.03%	163,115 $248,000
Q1 2022 May 16, 2022	SELL	$1.05 - $1.36 $489,720 - $634,304	-466,400 Reduced 61.12%	296,715 $389,000
Q4 2021 Feb 14, 2022	BUY	$1.04 - $1.34 $6,344 - $8,174	6,100 Added 0.81%	763,115 $946,000
Q3 2021 Nov 15, 2021	BUY	$1.18 - $1.64 $69,502 - $96,596	58,900 Added 8.44%	757,015 $1.05 Million
Q2 2021 Aug 16, 2021	BUY	$1.51 - $2.29 $833,369 - $1.26 Million	551,900 Added 377.46%	698,115 $1.19 Million
Q1 2021 May 17, 2021	BUY	$1.17 - $2.33 $59,017 - $117,529	50,442 Added 52.67%	146,215 $304,000
Q4 2020 Feb 16, 2021	SELL	$1.0 - $1.47 $1,700 - $2,499	-1,700 Reduced 1.74%	95,773 $110,000
Q3 2020 Nov 16, 2020	BUY	$1.09 - $2.21 $46,279 - $93,832	42,458 Added 77.18%	97,473 $106,000
Q2 2020 Aug 14, 2020	BUY	$1.8 - $3.05 $74,854 - $126,837	41,586 Added 309.67%	55,015 $137,000
Q1 2020 May 15, 2020	SELL	$1.91 - $4.08 $62,839 - $134,232	-32,900 Reduced 71.01%	13,429 $28,000
Q4 2019 Feb 14, 2020	BUY	$0.71 - $4.91 $3,239 - $22,404	4,563 Added 10.93%	46,329 $208,000
Q3 2019 Nov 14, 2019	BUY	$2.16 - $3.2 $90,214 - $133,651	41,766 New	41,766 $111,000

Others Institutions Holding SVRA

# of Institutions

128

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $338M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account